A Randomised Double Blind Placebo Controlled Dose-range Study Using Placebo, 1.5g and 3.0g of Intravenous Recombinant Interleukin-1 Receptor Antagonist (Anakinra) for Patients With Moderate-to-severe TBI
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Anakinra (Primary)
- Indications Inflammation
- Focus Therapeutic Use
- 10 Oct 2020 This trial has been Discontinued (Global End Date: 08 Sep 2020), according to European Clinical Trials Database record.
- 23 Jun 2019 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Oct 2017.